Lumasiran - Alnylam Pharmaceuticals

Drug Profile

Lumasiran - Alnylam Pharmaceuticals

Alternative Names: ALN-GO1; Lumasiran

Latest Information Update: 09 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Class Small interfering RNA
  • Mechanism of Action Glycolate oxidase expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Primary hyperoxaluria
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Primary hyperoxaluria

Most Recent Events

  • 03 Nov 2017 Positive preliminary efficacy and adverse events data from Part B of a phase I/II trial in Primary hyperoxaluria released by Alnylam Pharmaceuticals
  • 09 Oct 2017 Phase-II clinical trials in Primary hyperoxaluria (In adolescents, In children, In adults) in France (SC) (EudraCT2016-003134-24)
  • 14 Aug 2017 Alnylam Pharmaceuticals plans a phase II trial for Primary hyperoxaluria in Germany, Israel, Jordan, Netherlands, United Arab Emirates, United Kingdom and USA (EudraCT2016-003134-24)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top